Compare CMND & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMND | ACON |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 3.0M |
| IPO Year | 2021 | N/A |
| Metric | CMND | ACON |
|---|---|---|
| Price | $0.91 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 64.2K | 63.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $71.77 |
| Revenue Next Year | N/A | $80.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.61 |
| 52 Week High | $3.25 | $21.31 |
| Indicator | CMND | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 29.70 | 57.99 |
| Support Level | $0.80 | $2.38 |
| Resistance Level | $1.07 | $7.84 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 10.59 | 89.62 |
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.